The prescribing monitoring suite of searches has undergone review by our team of clinical pharmacists in accordance with current national guidelines. The following changes are due to reviewing NICE, NHSE or SPS guidance.
Below is a summary of changes that Ardens users may notice. If local resources have been created linking to an Ardens report, these may produce error messages.
NEW
- On atomoxetine <=10y | No weight in last 3m
- On dexamfetamine <=10y | No weight in last 3m
- On guanfacine <=10y | No weight in last 3m
- On lisdexamfetamine <=10y | No weight in last 3m
- On methylphenidate <=10y | No weight in last 3m
- On NSAID | No UE in last 1y ('On NSAID' defined on SystmOne as on repeat and >=3 issues in last year)
AMENDMENTS
- On digoxin | No UE in last 1y (calcium and magnesium removed)
- On metformin | No UE in last 6m if eGFR<60 or age >=65y (include elderly, i.e >=65y)
- On biologic DMARD | No FBC, UE or LFT in last 6m (name change to biologic DMARD)
REMOVED
- On phenytoin | No FBC, UE, LFT, Ca or Vit D in last 5y (lack of clear guidance)
Invite reports
Where monitoring has been added, a patient may now appear as being overdue despite attending recently for blood tests or monitoring.
The monitoring invite reports will undergo a restructure to align with other invite reports across the Ardens system. There will be a separate invite report with cohorts of people you may wish to alter their invitation method or review before inviting. These are to align with our other invitation reports within Ardens. These will be released in a second phase of the roll-out, and further details will be provided in due course.